Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
Novartis
University of California, Irvine
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
OHSU Knight Cancer Institute
National Cancer Institute (NCI)
Institute of Hematology & Blood Diseases Hospital, China
Guangdong Provincial People's Hospital
Massachusetts General Hospital
Sanofi
Beijing 302 Hospital
Fred Hutchinson Cancer Center
PrECOG, LLC.
Institute of Hematology & Blood Diseases Hospital, China
Shanghai Jiao Tong University School of Medicine
Eastern Cooperative Oncology Group
Fred Hutchinson Cancer Center
University of Leipzig
Children's Mercy Hospital Kansas City
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)
Emory University
University of Ulm
Massachusetts General Hospital
Pfizer
Novartis
National Cancer Institute (NCI)
French Innovative Leukemia Organisation
University of Ulm
Jazz Pharmaceuticals
National Cancer Institute (NCI)
Hospital Israelita Albert Einstein
Roswell Park Cancer Institute
Karolinska University Hospital
SWOG Cancer Research Network
SWOG Cancer Research Network
SWOG Cancer Research Network
Memorial Sloan Kettering Cancer Center
University Hospital Muenster
Dana-Farber Cancer Institute